

YOU ARE INVITED TO ATTEND A  
**VIRTUAL DISEASE AWARENESS PROGRAM**

SPONSORED BY AGIOS PHARMACEUTICALS, INC.

# Pyruvate Kinase Deficiency: An Underrecognized Cause of Chronic Hemolytic Anemia

## 3 Options to Attend via Web

### VIRTUAL OPTION 1

Tuesday, March 23, 2021

Start Time: 12:00 PM CT

#### PRESENTED BY:

Jenny Despotovic, DO

Director

Texas Children's Hematology  
Center

Houston, Texas

### VIRTUAL OPTION 2

Wednesday, March 31, 2021

Start Time: 12:00 PM ET

#### PRESENTED BY:

Richard Drachtman, MD

Clinical Section Chief, Pediatric  
Hematology/Oncology Division

Rutgers Cancer Institute of  
New Jersey

New Brunswick, New Jersey

### VIRTUAL OPTION 3

Thursday, April 8, 2021

Start Time: 2:00 PM CT

#### PRESENTED BY:

Jenny Despotovic, DO

Director

Texas Children's Hematology  
Center

Houston, Texas

***Log-in details for your selected option will be provided following registration.***

Please plan to log in 5-10 minutes prior to your preferred option to ensure the presentation can start on time.

#### THIS EDUCATIONAL PROGRAM WILL:

- Review the epidemiology and pathophysiology of pyruvate kinase (PK) deficiency in the United States
- Provide an overview of the clinical manifestations of PK deficiency and associated complications
- Outline recommendations for diagnosing and managing PK deficiency

**This virtual program is educational in nature and does not promote or endorse a pharmaceutical product.**

Register for Your Preferred Option at:

**[www.AgiosPKDregistration.com](http://www.AgiosPKDregistration.com)**

Should you prefer to register by phone, call **855-802-3429**.

#### Attendee and Reporting Policy

This educational program is intended for US healthcare professionals only. Guests and spouses may not attend this program. The value of any meals or items provided to program participants may be reported in accordance with applicable federal and state laws. Healthcare professionals from certain states or institutions that restrict healthcare professionals from accepting meals or other transfers of value from pharmaceutical companies must adhere to all restrictions and requirements imposed by the law or their institution.